32 reports of this reaction
3.7% of all TETRACAINE reports
#2 most reported adverse reaction
ENDOPHTHALMITIS is the #2 most commonly reported adverse reaction for TETRACAINE, manufactured by Bellus Medical, LLC. There are 32 FDA adverse event reports linking TETRACAINE to ENDOPHTHALMITIS. This represents approximately 3.7% of all 876 adverse event reports for this drug.
Patients taking TETRACAINE who experience endophthalmitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ENDOPHTHALMITIS is moderately reported among TETRACAINE users, representing a notable but not dominant share of adverse events.
In addition to endophthalmitis, the following adverse reactions have been reported for TETRACAINE:
The following drugs have also been linked to endophthalmitis in FDA adverse event reports:
ENDOPHTHALMITIS has been reported as an adverse event in 32 FDA reports for TETRACAINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ENDOPHTHALMITIS accounts for approximately 3.7% of all adverse event reports for TETRACAINE, making it one of the most commonly reported side effect.
If you experience endophthalmitis while taking TETRACAINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.